Natural History of Type 1 Interferonopathies: Insights From a European Cohort
NCT ID: NCT07040774
Last Updated: 2026-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2025-10-01
2045-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.
In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.
The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.
The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Acute Autoimmune Encephalitis With Positive Antibodies in Eastern France
NCT05605223
A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease
NCT05095623
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
NCT04902807
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
NCT06762002
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
NCT02257866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients with genetically confirmed type I interferonopathy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient affiliated to a social security scheme or beneficiary of such a scheme.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imagine Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University Innsbruck
Innsbruck, , Austria
Antwerp University Hospital
Antwerp, , Belgium
Children's Hospital Zagreb
Zagreb, , Croatia
Motol University Hospital
Prague, , Czechia
CHU d'Angers
Angers, , France
Hôpital de Mercy - CHR Metz Thionville
Ars-Laquenexy, , France
CHU de Besançon
Besançon, , France
CHU de Bordeaux
Bordeaux, , France
CHU Morvan
Brest, , France
Hôpital Femme Mère Enfant - HCL
Bron, , France
CHU de Dijon
Dijon, , France
Hôpitaux Nord Ouest Villefranche
Gleizé, , France
Hôpital Bicêtre
Le Kremlin-Bicêtre, , France
Hôpital Claude Huriez, CHU de Lille
Lille, , France
APHM Hôpitaux de Marseille
Marseille, , France
CHU de Montpellier
Montpellier, , France
CHRU Nancy
Nancy, , France
CHU de Nantes
Nantes, , France
CH Agen-Nérac
Nérac, , France
Hôpital de l'Archet
Nice, , France
Hôpital Armand Trousseau
Paris, , France
Hôpital Bichat
Paris, , France
Hôpital Robert Debré
Paris, , France
Hôpital des Enfants - CHU de Toulouse
Toulouse, , France
Hôpital Necker Enfants Malades
Paris, Île-de-France Region, France
University of Tübingen
Tübingen, , Germany
Meyer Children's Hospital IRCCS
Florence, , Italy
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Son Espases
Palma de Mallorca, , Spain
Karolinska University Hospital
Stockholm, , Sweden
Hacettepe İhsan Doğramacı Children's Hospital
Ankara, , Turkey (Türkiye)
Leeds Teaching Hospitals NHS Trust
Leeds, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alenka GAGRO, Dr
Role: primary
Özlem SATIRER
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HJ-24-EU-IFNp
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.